Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker

Soichiro Nagao; Yohei Yabuuchi; Kosuke Tanaka; Yoshiki Morihisa; Takuya Kobayashi; Shinsuke Akiyama; Gensho Tanke; Masaya Wada; Shuko Morita; Satoko Inoue; Hiroshi Tei; Daisuke Yamashita; Tetsuro Inokuma

doi:10.2169/internalmedicine.2857-23

This article has now been updated. Please use the final version.

Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker

Soichiro Nagao, Yohei Yabuuchi, Kosuke Tanaka, Yoshiki Morihisa, Takuya Kobayashi, Shinsuke Akiyama, Gensho Tanke, Masaya Wada, Shuko Morita, Satoko Inoue, Hiroshi Tei, Daisuke Yamashita, Tetsuro Inokuma

Author information

Keywords: neuroendocrine tumor, hypergastrinemia, proton pump inhibitor, potassium-competitive acid blocker

JOURNAL OPEN ACCESS Advance online publication

Article ID: 2857-23

DOI https://doi.org/10.2169/internalmedicine.2857-23

The final version of this article is now available: Vol. 63 (2024), No. 14 pp. 2001-2010

Details

Abstract

A 52-year-old man who had been using a proton pump inhibitor (PPI) and a potassium-competitive acid blocker (P-CAB) for 14 years underwent esophagogastroduodenoscopy and was found to have three neuroendocrine tumors (NETs) in the gastric body. Following detailed examinations, parietal cell dysfunction was excluded, and the NETs did not meet the criteria for the Rindi classification types I-III. The lesions were ultimately considered to be associated with the long-term use of the PPI and P-CAB. We performed endoscopic submucosal dissection of the lesions, with no recurrence or new lesions noted after discontinuation of the PPI and P-CAB.

Corresponding author

Register with J-STAGE for free!